Catalyst

Slingshot members are tracking this event:

Alder (ALDR) Plans to Announce Top-Line Data From 24 Week Phase 2b Study of ALD-403 in Chronic Migraine Patients By Mid-Year 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ALDR

100%

Additional Information

Additional Relevant Details Overview of product pipeline
http://www.alderbio....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 15, 2016
Occurred Source:
Related Keywords Phase 2b Follow-on Study, Optimal Dosing For Efficacy, 12-week Period, Frequent Episodic Migraine Patients, Ald403